secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEUROCRINE BIOSCIENCES INC (NBIX)
CIK:        0000914475
Form:       8-K
Filed at:   2024-05-01T23:59:59+00:00
Accession:  0000914475-24-000116
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neurocrine Q1: INGREZZA sales $506M (+23% YoY); GAAP EPS $0.42, non-GAAP EPS $1.20
--------------------------------------------------------------------------------

- INGREZZA net product sales $506M in Q1 2024 vs $411M in Q1 2023, up 23% year-over-year.
- GAAP net income $43.4M ($0.42 diluted EPS) vs net loss $76.6M ($0.79 loss) in Q1 2023.
- Non-GAAP net income $124.8M ($1.20 diluted EPS) vs net loss $49.5M ($0.51 loss) a year ago.
- Total revenues $515.3M (+23% YoY); cash & equivalents $1.91B at quarter end.
- FDA approved INGREZZA SPRINKLE; NDAs submitted for crinecerfont in congenital adrenal hyperplasia.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/914475/000091447524000116/0000914475-24-000116-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/914475/000091447524000116/nbix-20240501.htm
  HTML page:      https://secwatch.observer/filing/0000914475-24-000116

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer